



## Curriculum Vitae

### Personal information Federico De Angelis

#### Work experience

1. Employer: Academic Hospital of Sapienza University "Umberto I\_Policlinico di Roma"
  - Start date: 062015
  - End date: 032017
  - Position: Medical Physician\_Temporary Contract \_Haematology Division
  - Activities: Clinical and scientific activity in Haematology
  - Country: Italy
2. Employer: Novartis Pharma
  - Start date: 042017
  - End date: 032020
  - Position: Field Medical Advisor, Cell Therapy Medical Manager
  - Activities: Task Support for Medical Affairs of Novartis Pharma for Ruxolitinib and Tisagenlecleucel
  - Country: Italy
3. Employer: Italian National Health Service\_ Local Health Agency of Frosinone
  - Start date: 052020
  - End date: 112022
  - Position: Medical Physician in Haematology and Immunohaematology
  - Activities: Clinical activity in Haematology and Immuno\_haematology Department. Responsible for the JACIE and National Italian Transplant Network accreditation for apheresis of Stem Cell Collection
  - Country: Italy
4. Employer: Italian Medicines Agency\_AIFA
  - Start date: 112022
  - End date:
  - Position: Medical Officer
  - Activities: Innovation and Pharmaceutical Strategy Division Centralised Procedures Office
  - Country: Italy

#### Education and training

- Subject: Sapienza University of Rome
  - Start date: 092003
  - End date: 092009
  - Qualification: Medical Licensure, 110/110 cum laude
  - Organisation:
  - Country: Italy
- Subject: Sapienza University of Rome
  - Start date: 042010
  - End date: 062015
  - Qualification: Fellowship in Haematology, 70/70 cum laude
  - Organisation:
  - Country: Italy
- Subject: ICMED\_HQM Research Centre
  - Start date: 042022
  - End date: 042022
  - Qualification: CAR\_T SPECIALIST e GENE THERAPY EXPERT \_ Advance Edition
  - Organisation: CAR\_T and Gene Therapy advanced level course
  - Country: Italy
- Subject: Harvard Medical School, On Line Learning Course
  - Start date: 112020
  - End date: 112020
  - Qualification: "Fundamental in Immunology" Training Course
  - Organisation: Clinical and Experimental Immunology
  - Country: United States
- Subject: Advanced Training Course in Biostatistic and research methodology
  - Start date: 012023
  - End date: 012024
  - Qualification: Advanced training course in Biostatistic and research methodology
  - Country: Italy

#### Additional information

##### Publications

Author and co\_author of the following international publications: \_ Bruni R, Marcantonio C, Pulsoni A, Tataseo P, De Angelis F et al. "MicroRNA levels in paraffin\_embedded indolent B\_cell non\_Hodgkin lymphoma tissues from patients chronically infected with hepatitis B or C virus." BMC Infect Dis. 2014;14 Suppl 5:S6. (IF: 2.561) \_ Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, et al. "Rituximab maintenance compared with observation after brief first\_line R\_FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi." J Clin Oncol. 2013 Sep 20;31(27):3351\_9. (IF: 17.879) \_ Ladetto M, Lobetti\_Bodoni C, Mantoan B, et al. Collaborators (71) De Angelis F et al.; Fondazione Italiana Linfomi. "Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab\_intensive program." Blood. 2013 Nov 28;122(23):3759\_66. (IF:

9.775) \_ Panfilio S, D'Urso P, Annechini G, D'Elia GM, De Angelis F et al. "Regression of a case of Multiple Myeloma with antiviral treatment in a patient with chronic HCV infection". *Leuk Res Rep.* 2013 May 17;2(1):39\_40. \_ Capria S, De Angelis F, Gentile G et al. Complete remission obtained with azacitidine in a patient with concomitant therapy related myeloid neoplasm and pulmonary mucormycosis. *Mediterr J Hematol Infect Dis.* 2013 Jul 10;5(1): e20133048 \_ De Angelis F, Di Rocco A, Minotti C et al. "Atypical presentation of anaplastic large T\_cell lymphoma mimicking an articular relapse of rheumatoid arthritis in a patient treated with etanercept. A case report and literature review." *Leuk Res.* 2012 Sep;36(9):e199\_201. (IF: 2.764) \_ De Angelis F, Foà R: Follicular Lymphoma Exp. *Oncol.* 2012 Dec;34(4):380\_3 \_ De Angelis F, Annechini G, Agostinelli C, et al. Primary Uterine localization of Malt Lymphoma: a case report and literature review. *Leuk Res.* 2011 Nov;35(11):e185\_7. (IF:2.923) \_ D'Elia GM, De Angelis F., Breccia M. et al. Efficacy of bendamustine as salvage treatment in an heavily pre\_treated Hodgkin lymphoma. *Leuk Res* 2010 Nov;34(11):e300\_1. (IF: 2.555) \_ Cavalieri E, Matturro A, Annechini G, De Angelis F, et al. "Efficacy of the BEACOPP regimen in refractory and relapsed Hodgkin lymphoma" *Leukemia & Lymphoma*, November 2009; 50 (11):1803\_1808 (IF: 2.397) \_ Santoro C, Di Mauro R, Baldacci E, De Angelis F et al. Bleeding phenotype and correlation with factor XI (FXI) activity in congenital FXI deficiency: results of a retrospective study from a single centre. *Haemophilia.* 2015 Jan 27. doi: 10.1111/hae.12628. (IF: 2.468) \_ Latagliata R, Romano A, Mancini M, Breccia M, Carmosino I, Vozella F, Montagna C, Volpicelli P, De Angelis F, et al. Discontinuation of Alpha\_Interferon Treatment in Patients with Chronic Myeloid Leukemia in Long\_Lasting Complete Molecular Response. *Leuk Lymphoma.* 2015 May 22:1\_17. (IF:2.89) \_ Breccia M, Colafigli G, Molica M, De Angelis F et al. Sex correlates with differences in long\_term outcome in chronic myeloid leukaemia patients treated with imatinib. *Br J Haematol.* 2015 Aug 25. doi: 10.1111/bjh.13649. [Epub ahead of print] (I.F: 4.71) \_ De Angelis F, Tosti ME, Capria S et al. Risk of secondary hypogammaglobulinaemia after Rituximab and Fludarabine in indolent non\_Hodgkin lymphomas: A retrospective cohort study. *Leuk Res.* 2015 Nov 4. pii: S0145\_2126(15)30538\_5. (I.F. 2.35) \_ De Angelis F, Massimo Breccia. Molecular Monitoring as a Path to Cure Acute Promyelocytic Leukemia. *Rare Cancers Ther* (2015) 3:119-132 \_ Latagliata R, Carmosino I, Vozella F, Volpicelli P, De Angelis F et al. Impact of exclusion criteria for the DASISION and ENESTnd trials in the front\_line treatment of a 'real\_life' patient population with chronic myeloid leukaemia. *Hematol Oncol.* 2015 Dec 9. doi: 10.1002/hon.2274. (I.F. 3.08) \_ Mazzucconi MG, Santoro C, Baldacci E, De Angelis F et al. "TPO\_RAs in pITP: description of a case series and analysis of predictive factors for response". *Eur J Haematol.* 2016 Oct 31(I.F. 2.54) \_ Di Rocco A, De Angelis F, Ansuinelli M, et al. "Is now the time for molecular driven therapy for diffuse large B\_cell lymphoma?" *Expert Rev Hematol.* 2017 Sep;10(9):761\_774. Co\_author of chapters 42 (Trombophilia) e 43 (Trombosi, tromboembolismo e malattia tromboembolica) of academic book "Ematologia di Mandelli" Ed. Piccin,2014

#### Projects

2014 Collaboration at the EU Project "ERN (European Reference Network)\_Oncohematology in adult" for the accreditation project of the Haematology Department of Sapienza University 2020 Regional reference member on behalf of the "Lazio Region Blood Centre" for the EU Project "EU CCP ESI\_ Capacity Building for Collection of Covid\_19 Convalescent Plasma Under The Emergency Support Instrument" 2021 Responsible for the Italian National Transplant Centre\_ Apheresis and Stem Cell Collection\_ accreditation process

#### Memberships

#### Other Relevant Information